Pharmacometric Evaluation of Umbilical Cord Blood Concentration-Based Early Initiation of Treatment in Methadone-Exposed Preterm Neonates
- PMID: 33668712
- PMCID: PMC7996295
- DOI: 10.3390/children8030174
Pharmacometric Evaluation of Umbilical Cord Blood Concentration-Based Early Initiation of Treatment in Methadone-Exposed Preterm Neonates
Abstract
In methadone-exposed preterm neonates, early identification of those at risk of severe neonatal abstinence syndrome (NAS) and use of a methadone dosing regimen that can provide effective and safe drug exposure are two important aspects of optimal care. To this end, we reviewed 17 methadone dosing recommendations in the international guidelines and literature and explored their variability in key dosing strategies. We selected three of the reviewed dosing regimens for their pharmacokinetics (PK) characteristics and their exposure-response relationship in three gestational age groups of preterm neonates (28, 32 and 36 gestational age weeks) at risk for development of severe NAS (defined as an umbilical cord methadone concentration of ≤60 ng/mL, following fetal exposure). We applied early (12 h after birth) vs. typical (36 h after birth) initiation of treatment. We observed that use of universally recommended dosing regimens in preterm neonates can result in under- or over-exposure. Use of a PK-guided dosing regimen resulted in effective target exposures within 24 h after birth with early initiation of treatment (12 h after birth). Future prospective studies should explore the incorporation of umbilical cord methadone concentrations for early identification of preterm neonates at risk of developing severe NAS and investigate the use of a PK-guided methadone dosing regimen, so that treatment failure, prolonged length of stay and opioid over-exposure can be avoided.
Keywords: dosing; methadone; neonatal abstinence syndrome; preterm neonate.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Methadone dosing strategies in preterm neonates can be simplified.Br J Clin Pharmacol. 2019 Jun;85(6):1348-1356. doi: 10.1111/bcp.13906. Epub 2019 Apr 10. Br J Clin Pharmacol. 2019. PMID: 30805946 Free PMC article.
-
Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.Drug Alcohol Depend. 2013 Nov 1;133(1):266-9. doi: 10.1016/j.drugalcdep.2013.06.004. Epub 2013 Jul 8. Drug Alcohol Depend. 2013. PMID: 23845658 Free PMC article.
-
Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.Addiction. 2012 Nov;107 Suppl 1(0 1):53-62. doi: 10.1111/j.1360-0443.2012.04039.x. Addiction. 2012. PMID: 23106927 Free PMC article. Clinical Trial.
-
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.J Clin Pharmacol. 2021 Jul;61(7):857-870. doi: 10.1002/jcph.1811. Epub 2021 Feb 1. J Clin Pharmacol. 2021. PMID: 33382111 Review.
-
Opioid dependence and pregnancy: minimizing stress on the fetal brain.Am J Obstet Gynecol. 2017 Mar;216(3):226-231. doi: 10.1016/j.ajog.2016.10.003. Epub 2016 Oct 8. Am J Obstet Gynecol. 2017. PMID: 27729254 Review.
Cited by
-
Neonatal Abstinence Syndrome: Prevention, Management and Outcomes: From Birth to Adulthood.Children (Basel). 2022 Jul 30;9(8):1151. doi: 10.3390/children9081151. Children (Basel). 2022. PMID: 36010042 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources